Avalyn Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Avalyn Pharma (AVLN).

Price Target Range — 3 Quarters

Analyst Consensus — 4 Analysts

4Buy

Consensus RatingOutperform# Analysts4Avg. Consensus PT$62Upside to Avg. PT+138.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 2, 2026	Raymond James	Tiago Fauth	Initiate	Outperform	$60
Aug 13, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$53→$57
May 26, 2026	Evercore ISI Group	Gavin Clark-Gartner	Initiate	Outperform	$51
May 26, 2026	Guggenheim	Seamus Fernandez	Initiate	Buy	$80
May 26, 2026	Morgan Stanley	Judah Frommer	Initiate	Overweight	$53

Analyst Ratings News

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.

Avi Kapoor

PRO
Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60

Raymond James analyst Tiago Fauth initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Outperform rating and announces Price Target of $60.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57

Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and raises the price target from $53 to $57.

Benzinga Newsdesk

This Lear Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday

Top Wall Street analysts upgraded LEA, BAH, TRV, and CGNX stocks, with higher price targets. See what analysts think of other stocks on rating page.

Avi Kapoor

PRO
Evercore ISI Group Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $51

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Outperform rating and announces Price Target of $51.

Benzinga Newsdesk

This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on AVLN stock.

Avi Kapoor

Avalyn Pharma Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Avalyn Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRO
Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60

PRO
Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57

This Lear Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday

PRO
Evercore ISI Group Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $51

This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

People Also Watch

People Also Watch

Avalyn Pharma Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Avalyn Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRORaymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60

PROMorgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57

This Lear Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday

PROEvercore ISI Group Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $51

This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

People Also Watch

People Also Watch

PRO
Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60

PRO
Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57

PRO
Evercore ISI Group Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $51